Development and specificities of anti-interferon neutralizing antibodies in patients with chronic hepatitis C treated with pegylated interferon-α

Clinical Microbiology and Infection

Volumn 18, Issue 10, 2012, Pages 1033-1039

  Scagnolari, C ^a   Trombetti, S ^a   Solda A ^a   Milella, M ^b   Gaeta, G B ^c   Angarano, G ^b   Scotto, G ^d   Caporaso, N ^e   Morisco, F ^e   Cozzolongo, R ^f   Giannelli, G ^b   Fasano, M ^b   Santantonio, T ^d   Antonelli, G ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF FOGGIA   (Italy)

^e UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^f NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Hepatitis C virus; Interferon; Neutralizing antibodies; Seroconversion; Sustained virological response

Indexed keywords

ALPHA INTERFERON; NEUTRALIZING ANTIBODY; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B;

ADULT; AGED; ANTIBODY SPECIFICITY; ARTICLE; FEMALE; HEPATITIS C; HUMAN; IMMUNOGENICITY; LEUKOCYTE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; TREATMENT DURATION; TREATMENT RESPONSE;

HEPATITIS C VIRUS;

EID: 84866144790     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2011.03729.x     Document Type: Article

References (29)

1. Poynard T, Yuen MF, Ratziu V, Lai CL. Viral hepatitis C. Lancet 2003; 362: 2095-2100.
2. Chen CH, Yu ML. Evolution of interferon-based therapy for chronic hepatitis C. Hepat Res Treat 2010; 2010: 140953.
3. Lange CM, Zeuzem S. IL28B single nucleotide polymorphisms in the treatment of hepatitis C. J Hepatol 2011; 55: 692-701.
4. Moraes Coelho HS, Villela-Nogueira CA. Predictors of response to chronic hepatitis C treatment. Ann Hepatol 2010; 9: 54-60.
5. Giannelli G, Guadagnino G, Dentico P, Antonelli G, Antonaci S. MxA and PKR expression in chronic hepatitis C. J Interferon Cytokine Res 2004; 24: 659-663.
6. Asahina Y, Izumi N, Umeda N et al. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon-α-2b and ribavirin. J Viral Hepat 2007; 14: 396-403.
7. van der Eijk AA, Vrolijk JM, Haagmans BL. Antibodies neutralizing peginterferon α during retreatment of hepatitis C. N Engl J Med 2006; 354: 1323-1324.
8. Santantonio T, Milella M, Antonelli G, Scagnolari C. Neutralizing antibodies to interferon-α in a chronic hepatitis C patient non-responder to pegylated interferon. J Hepatol 2006; 45: 759-761.
9. Halfon P, Pérusat S, Bourlière M et al. Neutralizing antibodies to interferon-α and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-α-2a and ribavirin (ANRS HC16 GAMMATRI substudy). J Med Virol 2010; 82: 2027-2031.
10. Antonelli G. Biological basis for a proper clinical application of α interferons. New Microbiol 2008; 31: 305-318.
11. Scagnolari C, Casato M, Bellomi F et al. Serum interferon (IFN)-neutralizing antibodies and bioactivities of IFNs in patients with severe type II essential mixed cryoglobulinemia. Clin Diagn Lab Immunol 2003; 10: 70-77.
12. Bagnato F, Clemenzi A, Scagnolari C et al. Neutralizing antibodies against endogenous interferon in myasthenia gravis patients. Eur Cytokine Netw 2004; 15: 24-29.
13. Kawade Y. Quantitation of neutralization of interferon by antibody. Methods Enzymol 1986; 119: 558-573.
14. Grossberg SE, Kawade Y. The expression of potency of neutralizing antibodies for interferons and other cytokines. Biotherapy 1997; 10: 93-98.
15. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody. II. Neutralizing antibody unitage and its relationship to bioassay sensitivity: the tenfold reduction unit. J Interferon Cytokine Res 2001; 21: 743-755.
16. Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2003; 2: 214-221.
17. Singh SK. Impact of product-related factors on immunogenicity of biotherapeutics. J Pharm Sci 2011; 100: 354-387.
18. Antonelli G. In vivo development of antibody to interferons: an update to 1996. J Interferon Cytokine Res 1997; 17: S39-S46.
19. Rönnblom LE, Janson ET, Perers A, Oberg KE, Alm GV. Characterization of anti-interferon-α antibodies appearing during recombinant interferon-α 2a treatment. Clin Exp Immunol 1992; 89: 330-335.
20. Prümmer O. Interferon-α antibodies in patients with renal cell carcinoma treated with recombinant interferon-α-2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer 1993; 71: 1828-1834.
21. Brand CM, Leadbeater L, Bellati G, Marotta F, Ideo G. Antibodies developing against a single recombinant interferon protein may neutralize many other interferon-α subtypes. J Interferon Res 1993; 13: 121-125.
22. Jorns C, Holzinger D, Thimme R et al. Rapid and simple detection of IFN-neutralizing antibodies in chronic hepatitis C non-responsive to IFN-α. J Med Virol 2006; 78: 74-82.
23. Nolte KU, Günther G, von Wussow P. Epitopes recognized by neutralizing therapy-induced human anti-interferon-α antibodies are localized within the N-terminal functional domain of recombinant interferon-α 2. Eur J Immunol 1996; 26: 2155-2159.
24. Milella M, Antonelli G, Santantonio T et al. Neutralizing antibodies to recombinant-α-interferon and response to therapy in chronic hepatitis C virus infection. Liver 1993; 13: 146-150.
25. Leroy V, Baud M, de Traversay C, Maynard-Muet M, Lebon P, Zarski JP. Role of anti-interferon antibodies in breakthrough occurrence during-α 2a and 2b therapy in patients with chronic hepatitis C. J Hepatol 1998; 28: 375-381.
26. Bonetti P, Diodati G, Drago C et al. Interferon antibodies in patients with chronic hepatitic C virus infection treated with recombinant interferon-α 2a. J Hepatol 1994; 20: 416-420.
27. Goodin DS, Frohman EM, Hurwitz B et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2007; 68: 977-984.
28. Milella M, Antonelli G, Santantonio T et al. Treatment with natural IFN of hepatitis C patients with or without antibodies to recombinant IFN. Hepatogastroenterology 1995; 42: 201-204.
29. Berg T, Hopf U, Schuff-Werner P. Sustained remission of chronic hepatitis C after a change to human leukocyte interferon-α in a difficult-to-treat patient with breakthrough phenomenon associated with antibodies against recombinant interferon-α. Am J Gastroenterol 2001; 96: 612-614.